Variant report
Variant | nsv525902 |
---|---|
Chromosome Location | chr9:3014254-3022906 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:7)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
(count:7 , 50 per page) page:
1
No. | Transcrition factor | Chromosome Location | Cell Line | Cell type | Cell Stage | Matched TF binding sites |
---|---|---|---|---|---|---|
1 | FAM48A | chr9:3016491-3016563 | GM12878 | blood: | n/a | n/a |
2 | FOXA1 | chr9:3018034-3018343 | HepG2 | liver: | n/a | n/a |
3 | MAFK | chr9:3017925-3017956 | HepG2 | liver: | n/a | n/a |
4 | POLR2A | chr9:3014116-3014560 | H1-neurons | neurons: | n/a | n/a |
5 | POLR2A | chr9:3017055-3017096 | MCF10A-Er-Src | breast: | n/a | n/a |
6 | POLR2A | chr9:3014180-3014538 | H1-neurons | neurons: | n/a | n/a |
7 | REST | chr9:3013896-3014856 | H1-neurons | neurons: | n/a | n/a |
No data |
No data |
No data |
No data |
No data |
Variant related genes | Relation type |
---|---|
CARM1P1 | TF binding region |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs4543592 | chr9:3014254-3014255 | Enhancers Weak transcription | TF binding region | 1 gene(s) | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
2 | rs531942796 | chr9:3014277-3014278 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
3 | rs552266518 | chr9:3014301-3014302 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
4 | rs112897058 | chr9:3014308-3014309 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
5 | rs58404695 | chr9:3014310-3014311 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
6 | rs565611781 | chr9:3014311-3014312 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
7 | rs534846712 | chr9:3014319-3014320 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
8 | rs577057158 | chr9:3014327-3014328 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
9 | rs568384065 | chr9:3014328-3014329 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
10 | rs537338683 | chr9:3014349-3014350 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
11 | rs556488552 | chr9:3014391-3014392 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
12 | rs557244856 | chr9:3014429-3014430 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
13 | rs2327698 | chr9:3014477-3014478 | Enhancers Weak transcription | TF binding region | 1 gene(s) | LD-proxies of rSNPOverlapped rCNV | n/a |
14 | rs148029136 | chr9:3014491-3014492 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
15 | rs118053578 | chr9:3014500-3014501 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
16 | rs200074611 | chr9:3014526-3014527 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
17 | rs555885559 | chr9:3014537-3014538 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
18 | rs572424995 | chr9:3014540-3014541 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
19 | rs541642180 | chr9:3014567-3014568 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
20 | rs572615364 | chr9:3014569-3014570 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
21 | rs191684576 | chr9:3014570-3014571 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
22 | rs530188868 | chr9:3014600-3014601 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
23 | rs543716986 | chr9:3014607-3014608 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
24 | rs374199285 | chr9:3014611-3014612 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
25 | rs376212102 | chr9:3014618-3014619 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
26 | rs200334493 | chr9:3014642-3014643 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
27 | rs574520956 | chr9:3014656-3014657 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
28 | rs2327699 | chr9:3014702-3014703 | Enhancers Weak transcription | TF binding region | 1 gene(s) | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
29 | rs141753712 | chr9:3014731-3014732 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
30 | rs551866828 | chr9:3014800-3014801 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
31 | rs565802573 | chr9:3014808-3014809 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
32 | rs2327700 | chr9:3014813-3014814 | Enhancers Weak transcription | TF binding region | 1 gene(s) | LD-proxies of rSNPOverlapped rCNV | n/a |
33 | rs59763936 | chr9:3014819-3014820 | Enhancers Weak transcription | TF binding region | 1 gene(s) | LD-proxies of rSNPOverlapped rCNV | n/a |
34 | rs568265449 | chr9:3014826-3014827 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
35 | rs537201872 | chr9:3014895-3014896 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
36 | rs147196091 | chr9:3014903-3014904 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
37 | rs570728856 | chr9:3014930-3014931 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
38 | rs138705553 | chr9:3014956-3014957 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
39 | rs577030520 | chr9:3014957-3014958 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
40 | rs372350689 | chr9:3014966-3014967 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
41 | rs184238045 | chr9:3014970-3014971 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
42 | rs142752903 | chr9:3014988-3014989 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
43 | rs147341205 | chr9:3015030-3015031 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
44 | rs555008718 | chr9:3015034-3015035 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs574711256 | chr9:3015038-3015039 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs545798613 | chr9:3015106-3015107 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
47 | rs28485138 | chr9:3015158-3015159 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
48 | rs369479935 | chr9:3015213-3015214 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
49 | rs545840573 | chr9:3015214-3015215 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
50 | rs190185632 | chr9:3015222-3015223 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Gastric cancer | 16715143 | CNVD |
Glioblastoma multiforme | 22286061 | CNVD |
Esophageal squamous carcinoma | 18405350 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Intracranial aneurysm | 16715129 | CNVD |
Primary mediastinal b-cell lymphoma | 17728785 | CNVD |
Disorders of sex development | 22290220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Sudden cardiac death | 19188705 | CNVD |
Non-small cell lung cancer | 21829676 | CNVD |
Acute myeloid leukemia | 16864856 | CNVD |
Cancer | 21183584 | CNVD |
Non-small cell lung cancer | 21952639 | CNVD |
Disorders of sex development | 21048976 | CNVD |
Neuroblastoma | 18923191 | CNVD |
Intellectual disability | 22102821 | CNVD |
abnormal development | 18461090 | CNVD |
Honadal dysgenesis | 21048976 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Lung cancer | 16740712 | CNVD |
Malignant peripheral nerve sheath tumor | 18522746 | CNVD |
Basal cell lymphoma | 17170743 | CNVD |
Follicular lymphoma | 17170743 | CNVD |
Oral squamous cell carcinoma | 17134496 | CNVD |
Breast cancer | 16608533 | CNVD |
Hodgkin''s lymphoma | 18641027 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Breast cancer | 16272173 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Breast cancer | 17133270 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
Cervical cancer | 21063398 | CNVD |
Retinoblastoma | 22278416 | CNVD |
Splenic marginal zone lymphoma | 18492102 | CNVD |
Melanoma | 18172304 | CNVD |
Biliary cancer | 19435499 | CNVD |
Gastric cancer | 21586687 | CNVD |
Esophageal squamous carcinoma | 18350619 | CNVD |
Myopathy | 18421352 | CNVD |
Neuroblastoma | 18664255 | CNVD |
Acute lymphoblastic leukemia | 18957548 | CNVD |
Myeloproliferative neoplasm | 17564968 | CNVD |
Malignant meningioma | 17937814 | CNVD |
Glioma | 21971842 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Astrocytoma | 17387387 | CNVD |
Breast cancer | 17603634 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Glioblastoma multiforme | 17387387 | CNVD |
Hepatocellular carcinoma | 22174799 | CNVD |
Oligodendroglial tumors | 17285580 | CNVD |
Cutaneous squamous cell carcinomas | 19131950 | CNVD |
Small bowel adenocarcinoma | 21586687 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Chordoma | 18071362 | CNVD |
Acute lymphoblastic leukemia | 22237106 | CNVD |
Chordoma | 21602918 | CNVD |
Renal cell carcinoma | 18592004 | CNVD |
Developmental delay | 19490664 | CNVD |
Pleomorphic xanthoastrocytoma | 20730472 | CNVD |
microdeletion syndrome | 16199537 | CNVD |
Non-syndromic sensorineural hearing loss | 21987784 | CNVD |
Cancer | 20164919 | CNVD |
Chronic myeloid leukemia | 21384125 | CNVD |
Ovarian cancer | 21720365 | CNVD |
Non-syndromic sensorineural hearing loss | 21030649 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Developmental delay | 21147756 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Lung cancer | 18438408 | CNVD |
Autism | 20531469 | CNVD |
XY gonadal dysgenesis | 20685758 | CNVD |
Urothelial carcinoma | 21177765 | CNVD |
Oral cancer | 21386901 | CNVD |
lymphocytic leukemia | 21291569 | CNVD |
Acute lymphoblastic leukemia | 21339820 | CNVD |
Myelodysplastic syndrome | 21251322 | CNVD |
Breast cancer | 21785460 | CNVD |
Prostate cancer | 18632612 | CNVD |
Esophageal adenocarcinoma | 19417022 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Breast cancer | 21364760 | CNVD |
Breast cancer | 21858162 | CNVD |
Renal cell carcinoma | 21668985 | CNVD |
Autism | 22495311 | CNVD |
Gastrointestinal stromal cancer | 20877625 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Developmental delay | 21373258 | CNVD |
T-cell acute lymphoblastic leukemia | 18185524 | CNVD |
Malignant fibrous histiocytomas | 21085701 | CNVD |
Hepatocellular carcinoma | 18803288 | CNVD |
Ovarian cancer | 22355333 | CNVD |
Autism | 20808228 | CNVD |
Autism | 20858261 | CNVD |
Epilepsy | 20858261 | CNVD |
Mental retardation | 20858261 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr9:3007200-3018200 | Weak transcription | Fetal Brain Male | brain |
2 | chr9:3011600-3015000 | Enhancers | Primary monocytes fromperipheralblood | blood |
3 | chr9:3013200-3018400 | Weak transcription | Adipose Nuclei | Adipose |
4 | chr9:3013800-3015200 | Enhancers | Stomach Mucosa | stomach |
5 | chr9:3014200-3018200 | Weak transcription | Stomach Smooth Muscle | stomach |
6 | chr9:3015000-3018200 | Weak transcription | Fetal Lung | lung |
7 | chr9:3018000-3018200 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
8 | chr9:3018200-3018600 | Enhancers | Fetal Lung | lung |
9 | chr9:3018200-3019200 | Enhancers | Stomach Smooth Muscle | stomach |
10 | chr9:3018200-3019800 | Enhancers | Fetal Brain Male | brain |
11 | chr9:3018400-3019200 | Enhancers | Adipose Nuclei | Adipose |
12 | chr9:3018400-3019600 | Weak transcription | iPS-15b Cell Line | embryonic stem cell |
13 | chr9:3018600-3018800 | Weak transcription | Fetal Lung | lung |
14 | chr9:3018600-3019600 | Enhancers | Fetal Brain Female | brain |
15 | chr9:3018800-3019000 | Enhancers | Cortex derived primary cultured neurospheres | brain |
16 | chr9:3018800-3019000 | Enhancers | Ovary | ovary |
17 | chr9:3018800-3019200 | Enhancers | Brain Cingulate Gyrus | brain |
18 | chr9:3018800-3019200 | Enhancers | Fetal Lung | lung |
19 | chr9:3018800-3019200 | Enhancers | Fetal Muscle Leg | muscle |
20 | chr9:3018800-3020000 | Enhancers | Psoas Muscle | Psoas |
21 | chr9:3019200-3028000 | Weak transcription | Adipose Nuclei | Adipose |
22 | chr9:3019200-3028600 | Weak transcription | Fetal Muscle Leg | muscle |
23 | chr9:3019600-3020400 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
24 | chr9:3019800-3020600 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
25 | chr9:3020000-3020400 | Enhancers | HUES48 Cell Line | embryonic stem cell |
26 | chr9:3020000-3020400 | Enhancers | iPS-18 Cell Line | embryonic stem cell |